The company’s commitment is reflected in the development of innovative products for the protection and regeneration of the urothelium —such as hyaluronic acid-based formulations in pre-filled syringes and soft capsules— which help prevent and treat damage to the urinary mucosa in patients with recurrent urinary tract infections (rUTI), interstitial cystitis, or damage caused by radiation therapy and chemotherapy.
At the same time, IBSA also devotes significant attention to male conditions, such as erectile dysfunction, for which it has developed an innovative oral orodispersible film (ODF) formulation designed to improve treatment adherence and patients’ quality of life. Another area of focus is Peyronie’s disease, also known as induratio penis plastica, for which a hyaluronic acid-based treatment is available for the acute phase of the disease, representing a significant step forward in the clinical management of this condition.
